⌕
Odyssey Therapeutics · ODTX · Nasdaq
Tenet — · insufficient data
Compare
$18.34−3.37%At close
$18.34−0.64 (−3.37%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Odyssey Therapeutics (ODTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 10, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism

“Cutting Edge” article demonstrates that compared with IL-2, TNFR2 agonism promotes tissue-directed regulatory T-cell differentiation and lineage stability, as well as reduces autoimmune inflammation in preclinical model…

● GlobeNewsWireNov 4, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor $387…

● MarketBeatOct 25, 2026 · 12:03 ET
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Odyssey Therapeutics NASDAQ: ODTX presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor …

● Seeking AlphaOct 20, 2026 · 15:14 ET
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript

Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript…

● GlobeNewsWireOct 20, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026

Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD…

● GlobeNewsWireOct 6, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Compa…

● Defense WorldOct 5, 2026 · 04:15 ET
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages

Shares of Odyssey Therapeutics, Inc. (NASDAQ: ODTX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One investmen…

● Seeking AlphaSep 16, 2026 · 21:21 ET
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● GlobeNewsWireSep 16, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients sufferi…

● GlobeNewsWireAug 26, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Odyssey Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients sufferin…

No upcoming events in the feeds.

ANT24−6.6%
NVDA7−2.3%
FOX6−2.9%
AMD3−6.0%

Article counts from the last market-wide feed page, across every symbol we track and not just ODTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.